Northwest Biotherapeutics, Inc.

BST:NBYB Stock Report

Market Cap: €327.3m

Northwest Biotherapeutics Management

Management criteria checks 4/4

Northwest Biotherapeutics' CEO is Linda Powers, appointed in Jun 2011, has a tenure of 13.5 years. total yearly compensation is $925.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 2.24% of the company’s shares, worth €7.33M. The average tenure of the management team and the board of directors is 13.5 years and 19.3 years respectively.

Key information

Linda Powers

Chief executive officer

US$925.0k

Total compensation

CEO salary percentage100.0%
CEO tenure13.5yrs
CEO ownership2.2%
Management average tenure13.5yrs
Board average tenure19.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Linda Powers's remuneration changed compared to Northwest Biotherapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$71m

Jun 30 2024n/an/a

-US$76m

Mar 31 2024n/an/a

-US$72m

Dec 31 2023US$925kUS$925k

-US$64m

Sep 30 2023n/an/a

-US$78m

Jun 30 2023n/an/a

-US$87m

Mar 31 2023n/an/a

-US$102m

Dec 31 2022US$1mUS$700k

-US$105m

Sep 30 2022n/an/a

US$57m

Jun 30 2022n/an/a

US$135m

Mar 31 2022n/an/a

US$169m

Dec 31 2021US$1mUS$700k

US$179m

Sep 30 2021n/an/a

-US$234m

Jun 30 2021n/an/a

-US$474m

Mar 31 2021n/an/a

-US$537m

Dec 31 2020US$18mUS$700k

-US$530m

Sep 30 2020n/an/a

-US$243m

Jun 30 2020n/an/a

-US$56m

Mar 31 2020n/an/a

US$3m

Dec 31 2019US$802kUS$502k

-US$21m

Sep 30 2019n/an/a

-US$33m

Jun 30 2019n/an/a

-US$18m

Mar 31 2019n/an/a

-US$43m

Dec 31 2018US$7mUS$502k

-US$54m

Sep 30 2018n/an/a

-US$76m

Jun 30 2018n/an/a

-US$108m

Mar 31 2018n/an/a

-US$93m

Dec 31 2017US$502kUS$502k

-US$74m

Compensation vs Market: Linda's total compensation ($USD925.00K) is about average for companies of similar size in the German market ($USD1.02M).

Compensation vs Earnings: Linda's compensation has been consistent with company performance over the past year.

CEO

Linda Powers (68 yo)

13.5yrs

Tenure

US$925,000

Compensation

Ms. Linda F. Powers, J.D., has been Chief Financial Officer and Chief Accounting Officer at Northwest Biotherapeutics, Inc. since June 8, 2020. Ms. Powers has been the Chief Executive Officer and President...

Leadership Team

NamePositionTenureCompensationOwnership
Linda Powers
Chairperson13.5yrsUS$925.00k2.24%
€ 7.3m
Alton Boynton
Founder26.9yrsUS$375.00k0.23%
€ 742.4k
Marnix Bosch
Chief Technical Officer17.9yrsUS$453.60k2.69%
€ 8.8m
Leslie Goldman
Senior VP & General Counsel5.3yrsUS$725.00k0.013%
€ 43.0k
David Innes
Vice President of Investor Relations5.8yrsno datano data

13.5yrs

Average Tenure

73.5yo

Average Age

Experienced Management: NBYB's management team is seasoned and experienced (13.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Linda Powers
Chairperson17.6yrsUS$925.00k2.24%
€ 7.3m
Alton Boynton
Founder26.9yrsUS$375.00k0.23%
€ 742.4k
Henry Brem
Member of Clinical Advisory Board19.3yrsno datano data
Tom Mikkelsen
Member of Clinical Advisory Board19.3yrsno datano data
Linda Liau
Member of Scientific Advisory Board19.3yrsno datano data
Steven Brem
Member of Clinical Advisory Board19.3yrsno datano data
Darell Bigner
Member of Clinical Advisory Board19.3yrsno datano data
Navid Malik
Independent Director12.7yrsUS$150.00k1.83%
€ 6.0m
Pat Sarma
Independent Directorless than a yearno data0.95%
€ 3.1m
Samir Khleif
Member of Scientific Advisory Boardno datano datano data
Jerome Galon
Member of Scientific Advisory Boardno datano datano data
J. Black
Independent Director8.9yrsUS$150.00k0.49%
€ 1.6m

19.3yrs

Average Tenure

69.5yo

Average Age

Experienced Board: NBYB's board of directors are seasoned and experienced ( 19.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 05:19
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Northwest Biotherapeutics, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Boris PeakerOppenheimer & Co. Inc.
Pravin GondhaleVirtua Research Inc.
Guoqian ZengZacks Investment Research Inc.